NEW YORK, Sept. 13, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of CytRx Corporation (“CytRx” or the “Company”) (NASDAQ:CYTR) between November 18, 2014 and July 11, 2016.
You are hereby notified that a securities class action has commenced in the USDC for the Central District of California. If you purchased or otherwise acquired CytRx securities between November 18, 2014 and July 11, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/cytrx-corporation.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts including: (1) that the clinical hold placed on the Phase 3 trial of aldoxorubicin for soft tissue sarcomas (“STSs”) would prevent sufficient follow-up for patients involved in the study; (2) that, as a result, nearly half of all patients would be excluded from the data since the study was disturbed by a partial clinical hold; (3) that, in response, CytRx would likely conduct a second analysis; (4) and that the results of the trial could be materially affected and/or approval of aldoxorubicin for STS could be delayed.
If you suffered a loss in CytRx you have until September 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/cytrx-corporation.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 



